These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 38366286)

  • 1. Cost of Illness Analysis of Invasive Meningococcal Disease Caused by Neisseria Meningitidis Serogroup B in the Netherlands-a Holistic Approach.
    Zeevat F; Simons JJM; Westra TA; Wilschut JC; van Sorge NM; Boersma C; Postma MJ
    Infect Dis Ther; 2024 Mar; 13(3):481-499. PubMed ID: 38366286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost of illness of invasive meningococcal disease caused by serogroup B Neisseria meningitidis in Spain.
    Ivanova-Markova Y; González-Domínguez A; Hidalgo A; Sánchez R; García-Agua N; García-Ruiz AJ; Amanda Vallejo-Aparicio L; García A; Rodriguez R; de Gomensoro E; Gonzalez-Inchausti MDC; Shen J; Begum N; Tafalla M
    Vaccine; 2021 Dec; 39(52):7646-7654. PubMed ID: 34794819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cost-of-illness for invasive meningococcal disease caused by serogroup B Neisseria meningitidis (MenB) in Germany.
    Scholz S; Koerber F; Meszaros K; Fassbender RM; Ultsch B; Welte RR; Greiner W
    Vaccine; 2019 Mar; 37(12):1692-1701. PubMed ID: 30661834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Public Health Impact and Cost-Effectiveness Analysis of Routine Infant 4CMenB Vaccination in Germany to Prevent Serogroup B Invasive Meningococcal Disease.
    Scholz S; Schwarz M; Beck E; Meszaros K; Schneider M; Ultsch B; Greiner W
    Infect Dis Ther; 2022 Feb; 11(1):367-387. PubMed ID: 34877641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Public Health Impact and Cost-Effectiveness Analysis of 4-Component Meningococcal Serotype B Vaccination for Infants in France.
    de Pouvourville G; Breau-Brunel M; Loncle-Provot V; Beck E; Gaugain L; Nachbaur G; Pribil C
    Pharmacoecon Open; 2024 Jul; 8(4):539-557. PubMed ID: 38780884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modeling the public health impact of different meningococcal vaccination strategies with 4CMenB and MenACWY versus the current toddler MenACWY National Immunization Program in Chile.
    Graña MG; Cavada G; Vasquez M; Shen J; Maervoet J; Klint J; Gómez JA
    Hum Vaccin Immunother; 2021 Dec; 17(12):5603-5613. PubMed ID: 34890520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The quality-adjusted life-years loss due to serogroup B invasive meningococcal disease in Spain.
    García A; Vallejo-Aparicio LA; Begum N; Nikitas G; González-Inchausti C; de Gomensoro E
    Vaccine; 2024 Sep; 42(22):126155. PubMed ID: 39146857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequelae at Hospital Discharge in 61 Children With Invasive Meningococcal Disease, Chile, 2009-2019.
    Arteta-Acosta C; Villena Martínez R; Santolaya de Pablo ME
    Pediatr Infect Dis J; 2022 Aug; 41(8):607-613. PubMed ID: 35421054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The burden of invasive meningococcal disease in the Netherlands, 2011-2020.
    Middeldorp M; Steens A; Lagerweij G; van Sorge NM; Freudenburg-de Graaf W; A M Sanders E; de Melker HE; Knol MJ
    Vaccine; 2023 Apr; 41(16):2664-2670. PubMed ID: 36933982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The inpatient costs and hospital service use associated with invasive meningococcal disease in South Australian children.
    Wang B; Haji Ali Afzali H; Marshall H
    Vaccine; 2014 Aug; 32(37):4791-8. PubMed ID: 24998605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Culture-Confirmed Invasive Meningococcal Disease in Canada, 2010 to 2014: Characterization of Serogroup B
    Tsang RSW; Law DKS; De Paola R; Giuliani M; Stella M; Zhou J; Deng S; Boccadifuoco G; Giuliani MM; Serino L
    mSphere; 2020 Mar; 5(2):. PubMed ID: 32132156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidemiology and economic burden of meningococcal disease in Germany: A systematic review.
    Gruhn S; Witte J; Greiner W; Damm O; Dietzsch M; Kramer R; Knuf M
    Vaccine; 2022 Mar; 40(13):1932-1947. PubMed ID: 35227520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of invasive meningococcal disease case isolates in Atlantic Canada, 2014 to 2020: spatial-temporal variations of clones and predicted meningococcal B vaccine coverage.
    Tsang RSW; Law DKS; Zhou J; Haldane D; Garceau R; Zahariadis G; Mead K; Alexander D
    J Med Microbiol; 2022 Dec; 71(12):. PubMed ID: 36748536
    [No Abstract]   [Full Text] [Related]  

  • 14. Estimated strain coverage of serogroup B meningococcal vaccines: A retrospective study for disease and carrier strains in Greece (2010-2017).
    Tzanakaki G; Xirogianni A; Tsitsika A; Clark SA; Kesanopoulos K; Bratcher HB; Papandreou A; Rodrigues CMC; Maiden MCJ; Borrow R; Tsolia M
    Vaccine; 2021 Mar; 39(11):1621-1630. PubMed ID: 33597116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic evaluation of meningococcal serogroup B childhood vaccination in Ontario, Canada.
    Tu HA; Deeks SL; Morris SK; Strifler L; Crowcroft N; Jamieson FB; Kwong JC; Coyte PC; Krahn M; Sander B
    Vaccine; 2014 Sep; 32(42):5436-46. PubMed ID: 25131732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disease Burden of Invasive Meningococcal Disease in the Netherlands Between June 1999 and June 2011: A Subjective Role for Serogroup and Clonal Complex.
    Stoof SP; Rodenburg GD; Knol MJ; Rümke LW; Bovenkerk S; Berbers GA; Spanjaard L; van der Ende A; Sanders EA
    Clin Infect Dis; 2015 Oct; 61(8):1281-92. PubMed ID: 26123933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-Effectiveness of 4CMenB Infant Vaccination in England: A Comprehensive Valuation Considering the Broad Impact of Serogroup B Invasive Meningococcal Disease.
    Beck E; Klint J; Neine M; Garcia S; Meszaros K
    Value Health; 2021 Jan; 24(1):91-104. PubMed ID: 33431159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Demographic Features of Invasive Meningococcal Disease in Taiwan, 1993 to 2020, and Genetic Characteristics of Neisseria meningitidis Isolates, 2003 to 2020.
    Chiou CS; Liao YS; Chen BH; Lu MC; Hong YP; Wang YW; Teng RH
    Microbiol Spectr; 2022 Aug; 10(4):e0088222. PubMed ID: 35862973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidemiology of invasive meningococcal B disease in Australia, 1999-2015: priority populations for vaccination.
    Archer BN; Chiu CK; Jayasinghe SH; Richmond PC; McVernon J; Lahra MM; Andrews RM; McIntyre PB;
    Med J Aust; 2017 Nov; 207(9):382-387. PubMed ID: 29092704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Introduction of a second MenB vaccine into Europe - needs and opportunities for public health.
    Findlow J; Nuttens C; Kriz P
    Expert Rev Vaccines; 2019 Mar; 18(3):225-239. PubMed ID: 30821535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.